Georgia lawmakers at the Capitol have signed off on a measure that tells state health officials to keep close tabs on breakthroughs in sickle cell treatment while also nudging child-care centers to brief parents on a common respiratory virus. The Sickle Cell Disease Protection Act has cleared both chambers of the General Assembly and now waits on Gov. Brian Kemp for a final yes or no.
What the bill requires
House Bill 334 creates a new code section that instructs the Department of Community Health to conduct an annual review of medications, treatments and services available to Medicaid recipients with sickle cell disease, solicit public input, and publish a report on or before Jan. 15 each year, according to the bill's enrolled text on the Georgia General Assembly website. The measure also tells child-care learning centers and family child-care homes to provide parents with educational information about respiratory syncytial virus (RSV) by Sept. 1 each year.
Authorship and political notes
House Bill 334 was introduced by Rep. Omari Crawford (D‑Decatur) and attracted a slate of Democratic cosponsors, according to the bill tracker. "This ensures that Georgia's healthcare system stays up to date and provides life‑altering care," Crawford said in a statement to CBS Atlanta.
Who would be affected
Advocates say the measure could reach thousands of Georgians living with sickle cell disease. Georgia's Sickle Cell Data Collection work has identified roughly 16,000 people with SCD who have lived in the state, according to the Georgia Health Policy Center. Nationally, SCD is thought to affect about 100,000 people, and federal data show the disease occurs in about 1 in every 365 Black births and that more than 90% of people living with SCD in the U.S. are Black or African American, per the CDC.
Why timing matters
Supporters point to a surge in medical innovation for sickle cell disease, including two FDA‑approved cell‑based gene therapies cleared in December 2023, as a reason the state needs to move quickly to keep Medicaid coverage current, according to the U.S. Food and Drug Administration. Backers say the annual reviews are designed to give policymakers and clinicians a regular, clearer look at whether new drugs or treatments should be added to the state's Medicaid benefit package.
Advocates pushed the measure
Advocacy groups and families with loved ones living with sickle cell disease spent recent weeks lobbying at the Capitol, sharing accounts of delayed care and emergency visits that helped build momentum for the bill. GPB News reported that caregivers' testimony and outreach by the Sickle Cell Foundation of Georgia were central to persuading some lawmakers to support the change.
What happens next
The Senate passed a substitute version of HB 334, and the House later agreed to the changes in recorded votes. The measure is now headed to Gov. Kemp's desk for his signature or veto, per legislative records and coverage. The roll calls and enrolled bill text are available in the legislative record and on bill‑tracking pages such as LegiScan.
For thousands of families across Georgia, the bill promises a standing yearly review that could translate into faster Medicaid consideration of cutting‑edge treatments, but the new process will only take effect if and when the governor signs the bill into law.
